News

SAGA awarded €450,000 grant from Sweden’s SWElife Innovation Program

LUND, Sweden — /November 15, 2018/ — SAGA Diagnostics announced today it has been awarded a follow-on grant of SEK 4.7 million (~ €450,000) from the SWElife Accelerator Innovation Program to support the product development objectives of SAGA’s ultrasensitive technologies for monitoring cancer patients using simple blood samples and other…

Selected as a Top 500 Startup worldwide out of many thousands screened from over 100 countries

LUND, Sweden — /October 24, 2018/ — SAGA Diagnostics announces today that we have been selected as a Worldwide Top 500 Startup!  Out of many thousands of companies from over 100 countries screened, we were chosen by Hello Tomorrow and will participate in the Global Summit in Paris on March…

WntResearch selects SAGA’s ctDNA monitoring tool KROMA for phase 2 clinical trial

LUND, Sweden — /August 30, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has entered a customer agreement with WntResearch AB, a Swedish biopharma company advancing new anti-cancer therapies targeting…

SAGA inks deal with Center for Molecular Diagnostics for lung cancer and leukemia tests

LUND, Sweden — /June 14, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has entered a customer agreement with the Center for Molecular Diagnostics, Region Skåne, part of the Skåne…

IBSAFE results in acute myeloid leukemia presented at Keystone Symposium Stockholm

STOCKHOLM, Sweden — /May 8, 2018/ — Interim data on minimal residual disease (MRD) detection in acute myeloid leukemia (AML) patients was presented today by Dr. Louise Pettersson, MD (Pathology, Halmstad Hospital), at the Keystone Symposium on Precision Medicine in Cancer, Stockholm, Sweden.  Dr. Pettersson’s study was an abstract selected for…

Strong Winds Fill Sails of Successful Seed Round for SAGA Diagnostics

LUND, Sweden — /March 15, 2018/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces it has raised €1.0 million EUR seed capital from international investors (10.5 million SEK = $1.25 million USD). Participants…

Make a difference – join SAGA Diagnostics as Business Development Manager

[*** POSITION FILLED ***] Seeking a growth-oriented business development leader to join us in our mission to revolutionize cancer diagnostics and monitoring through proprietary ultrasensitive technologies to measure a new class of biomarker, circulating tumor DNA. Your role will include identifying, evaluating and executing transformative partnerships, collaborations, and deals across…

European Commission H2020 SME Instrument Phase 1 Grant Awarded!

We are pleased to announce that SAGA Diagnostics has been awarded the Phase 1 grant (€50,000) from the EU European Commission Horizon 2020 Program SME Instrument!  In this highly competitive commersialization program, our application was evaluated with top marks in all categories.  “Being awarded this grant is a strong signal…

SAGA Wins a SKAPA Innovation Award!

SAGA Diagnostics’ CEO Lao Saal (pictured 3rd from left) and CTO Anthony George were awarded the prestigious SKAPA Foundation Innovation Award in the Memory of Alfred Nobel for their development of ultrasensitive technologies to measure circulating tumor DNA.  Lao and Anthony are among two regional winners for Skåne in south…

SAGA wins 1st Place in NLSDays 2017 StartUp Pitch Competition!

Out of 16 Nordic companies, SAGA Diagnostics won 1st place for best pitch in the Nordic Life Science Days 2017 StartUp Pitch Competition, a Bionordic event sponsored by Johnson & Johnson Innovation, SmiLe Incubator and Medeon Science Park & Incubator. The award includes mentoring from Johnson & Johnson Innovation and complimentary registration…